Medical network - March 7 in February this year, the state administration for industry and commerce issued a law enforcement announcement of this phenomenon also has hit: wuhan emerging elite medicine get several production of methyl salicylate API manufacturing enterprises of the national total generation rights, which has 100% of the market, the market since 2015, the API by 20000 yuan/ton rose to the highest price 20000 yuan/ton.
In fact, API behind rising prices, related production enterprise cost pressure is not small.
Part of the API prices
"API prices not only this year, many companies over the years is in constant prices, in my impression, since 2015, our company products required by the API has experienced three times raise price, every time the rise of multiplied several level." Chongqing, a big drug firms executives told the "daily economic news" reporter, it has become one of the main factors of drug prices.
Facing upstream API prices sharply raising prices, the downstream preparation medicine companies are having to pay. "Because most chemical API manufacturers is less, many enterprises are underwriting through dealers, formed a monopoly in the market, there is no other choice." The drug companies executive said.
Reporter in the interview, also found that the current API manufacturers franchise from trading company agent has been belong to industry practices. "Manufacturer's raw materials are through the trading company to sell it to pharmaceutical companies, direct sales of basic no." Shaanxi st. medicine science and technology agents only manager said.
The cost of reversed transmission necessity
In the face of the downstream preparation medicine enterprise collective "questioning", the upstream API companies said they also have difficulties.
"In terms of our ex-factory price, the actual increase than the downstream enterprises to the low number of pleased, but because more than the middle trade links, lead to price up again." The relevant person in charge of an API enterprises in gansu province told the daily economic news "reporter in an interview.
The director also said that the rising cost of influencing factors, the environmental problem is also one of the "new" environmental law "in 2015, according to the standard processing industrial" three wastes ", our cost increase, at least in a multiple level."
Environmental governance effects downstream drug firms have. Last November, north China pharmaceutical has announced, from shijiazhuang to carry out the "sword action" of the pollution treatment, volatile organic compounds in principle for all production process at all, active pharmaceutical ingredients, in part, will affect the current profit is 50 million yuan.
In addition, the new three board listed companies the qi medicine co announced in December last year, because of environmental problems, the terramycin alkali production workshop from August to December this year has been shut down, lead to the company's performance is affected by a certain.
"Active pharmaceutical ingredients in the production process of waste water, waste gas, waste residue amount is larger, and the composition is complicated, has been the focus of the environmental protection check object, if the drug companies in strict accordance with the new" environmental law "to deal with" three wastes ", the production cost growth is normal." A veteran said chongqing environmental protection system, used to have a lot of drug companies will factory moved to the part of the western region, to achieve the purpose of reduce the environmental cost, but with the environmental protection law enforcement strict, the importance of environmental protection all over the country, enterprise can increase investment.
Chongqing, it is important to note that the above drug firms executives also said that the reason that our country is API, a core competence is the price is much lower than foreign products, but as prices rise, the core competitive position is lost. |
